AbbVie (ABBV) Proxy Filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on May 8, 2026, with voting on director elections, auditor ratification, executive compensation, a management proposal to eliminate supermajority voting, and a shareholder proposal on board leadership structure.

• The company reported strong operational execution in 2025, with $61.2B in net revenues (+8.5% operational growth), $19.0B in operating cash flow, and significant R&D investment of $13.8B.

• Market capitalization increased by $309B over the last decade, with a 204% dividend increase and a 485% total stockholder return, outperforming major indices and most peers.

Voting matters and shareholder proposals

• Four directors are up for election to serve until 2029.

• Ratification of Ernst & Young LLP as independent auditor for 2026 is recommended.

• Advisory vote on executive compensation (say-on-pay) is recommended for approval.

• Management proposes eliminating supermajority voting thresholds in the charter and by-laws.

• A shareholder proposal requests an independent board chair; the board recommends voting against it.

Board of directors and corporate governance

• Twelve of thirteen directors are independent; all key committees are fully independent.

• Recent board refreshment includes four new directors since 2023, a new lead independent director in 2024, and all new committee chairs in 2024.

• The board regularly reviews its leadership structure, currently combining CEO and chair roles with a robust lead independent director.

• Proxy access by-law allows 3%/3-year shareholders to nominate directors; no poison pill is in place.

• Board diversity: 38% female, 15% ethnically or racially diverse.